Clinical Trial

A Phase 1 Study of BB102 in Participants With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, efficacy and preliminary food effect of BB102, a highly selective and potent FGFR4 inhibitor, as monotherapy in subjects with advanced solid tumors. This study has two phase: dose escalation phase and expansion phase.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-02-06; most recent amendment 2025-11-13.
Trial Details
NCT Number NCT06258408
Lead Sponsor Broadenbio Ltd., Co.
Conditions Advanced Solid Tumor
Enrollment 78 participants
Start Date 2022-12-29
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-11-17